Dibekacin intrarenal distribution characteristics and renal cortical elution kinetics. Comparison with gentamicin and tobramycin.
Dibekacin (3',4-dideoxykanamycin B) is a new semisynthetic aminoglycoside developed in Japan and one which has found wide clinical acceptance in that country. The antibacterial activity of this compound indicates that it is relatively similar to gentamicin. Since it appears that the intrarenal distributional characteristics and renal cortical kinetics of aminoglycosides provide some predictive information concerning the clinical incidence of nephrotoxicity, we designed a series of pharmacokinetic studies in healthy mongrel dogs which would define such kinetic information for dibekacin and would contrast the results with similar studies for gentamicin and tobramycin. The renal cortical kinetics of dibekacin, as developed in these studies, show that in a canine model the behavior of dibekacin is similar to that of gentamicin and significantly different from tobramycin. Dibekacin and gentamicin show reproducibly higher renal cortical tissue concentrations than tobramycin in both the acute infusion studies and multiple dosing studies. The results suggest that dibekacin may possess the same inherent nephrotoxic potential as that of gentamicin. In order to show any difference in clinical toxicity between gentamicin and dibekacin, a very extensive randomized, double-blind, prospective clinical trial of efficacy and toxicity will be needed.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000378:metabolism*; D003982:Dibekacin / Q000378:metabolism*; D004285:Dogs; D005260:Female; D005839:Gentamicins / Q000378:metabolism*; D007612:Kanamycin / Q000031:analogs & derivatives*; D007668:Kidney / Q000378:metabolism; D007672:Kidney Cortex / Q000378:metabolism*; D007700:Kinetics; D014031:Tobramycin / Q000378:metabolism*
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D003982:Dibekacin; D007612:Kanamycin; D014031:Tobramycin